GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Cyclically Adjusted PB Ratio

VALN (Valneva SE) Cyclically Adjusted PB Ratio : 2.11 (As of May. 13, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Valneva SE Cyclically Adjusted PB Ratio?

As of today (2025-05-13), Valneva SE's current share price is $6.45. Valneva SE's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was $3.05. Valneva SE's Cyclically Adjusted PB Ratio for today is 2.11.

The historical rank and industry rank for Valneva SE's Cyclically Adjusted PB Ratio or its related term are showing as below:

VALN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.18   Med: 3.14   Max: 14.5
Current: 1.88

During the past years, Valneva SE's highest Cyclically Adjusted PB Ratio was 14.50. The lowest was 1.18. And the median was 3.14.

VALN's Cyclically Adjusted PB Ratio is ranked worse than
57.36% of 666 companies
in the Biotechnology industry
Industry Median: 1.465 vs VALN: 1.88

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Valneva SE's adjusted book value per share data for the three months ended in Dec. 2024 was $2.337. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.05 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Valneva SE Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Valneva SE's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Cyclically Adjusted PB Ratio Chart

Valneva SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.48 14.50 3.57 2.90 1.43

Valneva SE Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.90 2.28 2.04 1.74 1.43

Competitive Comparison of Valneva SE's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Valneva SE's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Valneva SE's Cyclically Adjusted PB Ratio falls into.


;
;

Valneva SE Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Valneva SE's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=6.45/3.05
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Valneva SE's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=2.337/119.9500*119.9500
=2.337

Current CPI (Dec. 2024) = 119.9500.

Valneva SE Quarterly Data

Book Value per Share CPI Adj_Book
201503 4.598 100.170 5.506
201506 4.543 100.440 5.425
201509 4.363 99.950 5.236
201512 4.210 100.040 5.048
201603 4.167 100.020 4.997
201606 3.025 100.630 3.606
201609 2.828 100.340 3.381
201612 2.685 100.650 3.200
201703 2.706 101.170 3.208
201706 2.805 101.320 3.321
201709 2.917 101.330 3.453
201712 2.832 101.850 3.335
201803 2.971 102.750 3.468
201806 2.732 103.370 3.170
201809 2.663 103.560 3.084
201812 3.583 103.470 4.154
201903 3.420 103.890 3.949
201906 3.237 104.580 3.713
201909 3.152 104.500 3.618
201912 3.308 104.980 3.780
202003 3.199 104.590 3.669
202006 2.751 104.790 3.149
202009 1.988 104.550 2.281
202012 2.075 104.960 2.371
202103 1.360 105.750 1.543
202106 1.862 106.340 2.100
202109 0.000 106.810 0.000
202112 3.669 107.850 4.081
202203 0.000 110.490 0.000
202206 1.682 112.550 1.793
202209 2.784 112.740 2.962
202212 3.365 114.160 3.536
202303 3.172 116.790 3.258
202306 2.978 117.650 3.036
202309 2.423 118.260 2.458
202312 2.015 118.390 2.042
202403 2.956 119.470 2.968
202406 2.573 120.200 2.568
202409 2.977 119.560 2.987
202412 2.337 119.950 2.337

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Valneva SE  (NAS:VALN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Valneva SE Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Valneva SE's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE Business Description

Industry
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.